No abstract available.
Animals ; Capsaicin* ; Colon* ; Cytokines* ; Lung* ; Melanoma, Experimental* ; Mice* ; RNA, Messenger*

A 49-year-old male was found unconscious at his accommodation and visited the emergency room. He was on antipsychotic and antidepressant drugs (vortioxetine hydrobromide, mirtazapine, sertraline hydrochloride, quetiapine, and alprazolam) for schizophrenia and major depression. At the time of discovery there were signs of overdose of the drugs around the patient. A physical examination revealed, pain, pallor, and edema in the left buttocks and lateral thigh. Active ankle movements below the left ankle were not possible and sensations in the tibia and peroneal nerves were lost. The pressure in the buttock compartment was measured at 42 mmHg. Magnetic resonance imaging revealed edema and high intensity signals in the left hip muscles and surrounding soft tissue. An emergency fasciotomy was performed and partial restoration of the lower extremity sensation and muscle strength were achieved after 24 hours.

No abstract available.
Humans ; Parents* ; Siblings*

PURPOSE: This study examined the effect of a self-help management program which strengthens self-efficacy on the self-efficacy and the activities of daily living(ADL) in stroke patients. METHODS: A quasi-experimental nonequivalent control group, pre and post design was used. The subjects consisted of 47 stroke patients. Twenty-six patients were assigned to the experimental group and 21 patients were assigned to the control group. The self-help management program by strengthen self-efficacy and general hospital care were carried out on the experimental group. General hospital care was performed on the control group. The data was collected before and 5 weeks after the program. All subjects were questioned about the self-efficacy and ADL before and after the program. RESULTS: The scores of the self-efficacy and ADL in the experimental group were higher than those in the control group. CONCLUSION: The self-help management program by strengthen self-efficacy is effective in increasing the self-efficacy and ADL. Therefore this program may be a useful intervention to increase the ADL in stroke patients.
Activities of Daily Living ; Hospitals, General ; Humans ; Stroke

PURPOSE: To assess the effect of oral Ginkgo biloba extract (EGB 761) on visual field in patients with normal tension glaucoma (NTG) based on the vascular theory among the machanisms of glaucomatous optic nerve damage. METHODS: A retrospective automated visual field data were obtained from Ginkgo group (20 patients, 38 eyes) and control group (20 patients, 40 eyes). Both groups underwent five Humphrey C24-2 field program over at least 4 years, and had glaucomatous optic nerve damage and visual field change, whose IOP were maintained under 21mmHg during all follow-up periods. Linear regression was performed with respect to mean deviation (MD), corrected pattern standard deviation (CPSD), and mean thresholds of Glaucoma Hemifield test (GHT). Subjects were classified as progressive, improvement, stationary based on the slope and statistical significance. RESULTS: There were 6 eyes (15.8%) with improvements with regard to MD in Ginkgo group. There were 5 eyes (13.2%) with improvements in Ginkgo group and 3 eyes (7.5%) with improvements in control group with regard to CPSD. With GHT cluster analysis, there were 13 eyes (34.2%) with improvements in Ginkgo group and 5 eyes (12.5%) with improvements in control group. CONCLUSIONS: The visual field in patient with NTG was improved in GBE group through MD, CPSD, and GHT cluster mean threshold, which was relatively compatible with known NTG visual field defect.
Follow-Up Studies ; Ginkgo biloba* ; Glaucoma ; Humans ; Linear Models ; Low Tension Glaucoma ; Optic Nerve ; Retrospective Studies ; Visual Field Tests ; Visual Fields*

We report one case of implant plate exposure after Ahmed valve implantation, treated with preserved fascia lata transplantation. Exposure of implant occurred in 47-year-old patient with Ahmed glaucoma valve implantation. She was treated with preserved fascia lata graft and amniotic membrane transplantation. No recurrent implant plate exposure has been found since then. Intraocular pressure has been maintained well for 3 months of follow-up. In cases of implant plate exposure, additional preserved fascia lata graft and amniotic membrane transplantation can improve surgical success.
Amnion ; Fascia ; Fascia Lata ; Follow-Up Studies ; Glaucoma ; Humans ; Intraocular Pressure ; Middle Aged ; Transplants

No abstract available.
Child* ; Humans ; Hypercalciuria*

No abstract available.
Calcium* ; Fetal Blood* ; Phosphorus*

No abstract available.
Constriction, Pathologic* ; Decompression* ; Laminectomy*

PURPOSE: To investigate the percentage and time of intraocular pressure (IOP) elevation and the factors influencing IOP elevation and treatment. METHODS: Thirty patients (33 eyes) who received intravitreal dexamethasone implantation from July 2012 to December 2013 and followed up more than 1 year were evaluated by measuring Goldmann IOP and confirming changes in IOP. The definition of IOP elevation was IOP above 20 mm Hg or IOP increase greater than 6 mm Hg. RESULTS: In 16 eyes (48.5%), IOP was elevated after intravitreal dexamethasone implantation. The first IOP elevation was mean 2.0 +/- 0.7 months. In 21 eyes which received intravitreal dexamethasone implantation more than twice, the mean intervals of implantation were 4.5 months. In steroid responders, IOP after dexamethasone implantation was significantly increased at 1, 2, 3, 6, and 7 months. IOP increase in the treated eye was significant at 1, 2, 3, 5, and 7 months after dexamethasone implantation. CONCLUSIONS: After intravitreal dexamethasone implantation, IOP was highest at 2 months. Additionally, IOP was elevated in approximately half of the patients (48.5%). Although the intravitreal dexamethasone implantation is effective against various diseases which occur due to macular edema, thorough identification of suitable patients and frequent IOP control is necessary for long-term treatment.
Dexamethasone* ; Follow-Up Studies* ; Humans ; Intraocular Pressure* ; Macular Edema